TABLE 1.
Group | Base | 10 | Initiation of IVRA | 10 | 20 | 30 | 40 | 50 | 60 | End of IVRA | 10 | 20 | 30 | 40 | 50 | 60 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (beats/min) | LID | 79 ± 14 | 103 ± 24 | 106 ± 29 | 122 ± 23 | 127 ± 18 | 121 ± 11 | 126 ± 12 | 129 ± 11 | 123 ± 27 | 137 ± 36 | 108 ± 23 | 89 ± 22 | 90 ± 11 | 82 ± 16 | ||
ROP | 87 ± 18 | 116 ± 21 | 125 ± 37 | 131 ± 33 | 133 ± 31 | 133 ± 34 | 131 ± 38 | 133 ± 25 ‡ | 127 ± 13 ‡ | 117 ± 17 | 125 ± 26 | 112 ± 29 | 107 ± 25 | 105 ± 33 | |||
MBP (mmHg) | LID | ND | 65 ± 5 | 71 ± 10 | 100 ± 31 | 104 ± 29 | 112 ± 32 | 119 ± 19 | 123 ± 27 | ND | ND | ND | ND | ND | ND | ||
ROP | ND | 73 ± 15 | 79 ± 32 | 75 ± 25 | 87 ± 30 | 95 ± 31 | 98 ± 30 | 102 ± 25 | ND | ND | ND | ND | ND | ND | |||
f R (breaths/min) | LID | 14 ± 2 | 8 ± 3 | 7 ± 3*, † | 9 ± 3* | 8 ± 2*, † | 9 ± 2* | 12 ± 4 | 14 ± 4* | 13 ± 4 | 14± 4 | 12 ± 3 | 13 ± 3 | 13 ± 2 | 13 ± 2 | ||
ROP | 17 ± 4 | 12 ± 3 | 17 ± 4 | 17 ± 4 | 17 ± 5 | 17 ± 3 | 24 ± 5 | 23 ± 4 | 19 ± 3 | 15 ± 2 | 14 ± 2 | 15 ± 2 | 16 ± 3 | 15 ± 2 | |||
RT (˚C) | LID | 38.6 ± 0.4 | 37.3 ± 0.3 | 37.3 ± 0.3 † | 37.4 ± 0.2 † | 37.4 ± 0.3 † | 37.2 ± 0.2 † | 37.3 ± 0.4 † | 37.3 ± 0.3 | 37.7 ± 0.3 | 37.3 ± 0.4 | 37.9 ± 0.4 | 38.2 ± 0.4 | 38.4 ± 0.5 | 38.5 ± 0.4 | ||
ROP | 38.5 ± 0.2 | 37.5 ± 0.3 ‡ | 37.0 ± 0.3 ‡ | 37.6 ± 0.2 | 37.6 ± 0.3 | 37.5 ± 0.4 | 37.4 ± 0.5 | 37.4 ± 0.4 | 37.6 ± 0.5 | 37.2 ± 0.4 | 37.8 ± 0.4 | 38.0 ± 0.3 | 38.3 ± 0.3 | 38.2 ± 0.3 |
Significantly different from other group (p < 0.05).
Significantly different from baseline in LID treatment (p < 0.05).
Significantly different from baseline in ROP treatment (p < 0.05).